Literature DB >> 10482905

The cannabinoid CB1 receptor antagonist, SR141716A, selectively facilitates nociceptive responses of dorsal horn neurones in the rat.

V Chapman1.   

Abstract

The effect of spinal administration of the selective cannabinoid CB1 receptor antagonist, SR141716A, and the selective CB2 receptor antagonist, SR144528, on innocuous versus noxious evoked responses of dorsal horn neurones in the spinal cord of the anaesthetized rat was investigated. SR141716A (0.001-1 ng 50 microl(-1)) dose-relatedly facilitated the non-potentiated component of the electrical C-fibre mediated neuronal response (120+/-6, 156+/-13, 192+/-33 and 192+/-31% of control respectively; n=6). In contrast, SR144528 (0.001-1 ng 50 microl(-1)) did not influence the non-potentiated component of the C-fibre evoked neuronal response (n=5). The electrical evoked Abeta-fibre mediated neuronal responses were not influenced by SR141716A or SR144528. The results of this study provide evidence that tonic cannabinoid CB1 receptor activation, but not CB2 receptor activation, attenuates acute nociceptive transmission, at the level of the spinal cord. These results suggest a selective antinociceptive role of the endogenous cannabinoids at spinal CB1 receptors.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10482905      PMCID: PMC1566187          DOI: 10.1038/sj.bjp.0702758

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  15 in total

1.  SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice.

Authors:  J D Richardson; L Aanonsen; K M Hargreaves
Journal:  Eur J Pharmacol       Date:  1997-01-29       Impact factor: 4.432

2.  Pre- and postsynaptic distribution of mu, delta and kappa opioid receptors in the superficial layers of the cervical dorsal horn of the rat spinal cord.

Authors:  D Besse; M C Lombard; J M Zajac; B P Roques; J M Besson
Journal:  Brain Res       Date:  1990-06-25       Impact factor: 3.252

3.  Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system.

Authors:  K Tsou; S Brown; M C Sañudo-Peña; K Mackie; J M Walker
Journal:  Neuroscience       Date:  1998-03       Impact factor: 3.590

4.  SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; J Millan; J M Derocq; P Casellas; C Congy; D Oustric; M Sarran; M Bouaboula; B Calandra; M Portier; D Shire; J C Brelière; G L Le Fur
Journal:  J Pharmacol Exp Ther       Date:  1998-02       Impact factor: 4.030

5.  Antihyperalgesic effects of spinal cannabinoids.

Authors:  J D Richardson; L Aanonsen; K M Hargreaves
Journal:  Eur J Pharmacol       Date:  1998-03-19       Impact factor: 4.432

6.  Localization of central cannabinoid CB1 receptor messenger RNA in neuronal subpopulations of rat dorsal root ganglia: a double-label in situ hybridization study.

Authors:  A G Hohmann; M Herkenham
Journal:  Neuroscience       Date:  1999-03       Impact factor: 3.590

7.  SR141716A, a potent and selective antagonist of the brain cannabinoid receptor.

Authors:  M Rinaldi-Carmona; F Barth; M Héaulme; D Shire; B Calandra; C Congy; S Martinez; J Maruani; G Néliat; D Caput
Journal:  FEBS Lett       Date:  1994-08-22       Impact factor: 4.124

8.  Hypoactivity of the spinal cannabinoid system results in NMDA-dependent hyperalgesia.

Authors:  J D Richardson; L Aanonsen; K M Hargreaves
Journal:  J Neurosci       Date:  1998-01-01       Impact factor: 6.167

9.  Electrophysiologic analysis of preemptive effects of spinal opioids on N-methyl-D-aspartate receptor-mediated events.

Authors:  V Chapman; J E Haley; A H Dickenson
Journal:  Anesthesiology       Date:  1994-12       Impact factor: 7.892

10.  Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors.

Authors:  S J MacLennan; P H Reynen; J Kwan; D W Bonhaus
Journal:  Br J Pharmacol       Date:  1998-06       Impact factor: 8.739

View more
  17 in total

1.  Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide.

Authors:  J Chemin; A Monteil; E Perez-Reyes; J Nargeot; P Lory
Journal:  EMBO J       Date:  2001-12-17       Impact factor: 11.598

Review 2.  The endocannabinoid system as an emerging target of pharmacotherapy.

Authors:  Pál Pacher; Sándor Bátkai; George Kunos
Journal:  Pharmacol Rev       Date:  2006-09       Impact factor: 25.468

3.  Cannabinoid actions on rat superficial medullary dorsal horn neurons in vitro.

Authors:  E A Jennings; C W Vaughan; M J Christie
Journal:  J Physiol       Date:  2001-08-01       Impact factor: 5.182

Review 4.  Modulation of pain transmission by G-protein-coupled receptors.

Authors:  Hui-Lin Pan; Zi-Zhen Wu; Hong-Yi Zhou; Shao-Rui Chen; Hong-Mei Zhang; De-Pei Li
Journal:  Pharmacol Ther       Date:  2007-09-22       Impact factor: 12.310

5.  Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve.

Authors:  Andrei V Derbenev; Thomas C Stuart; Bret N Smith
Journal:  J Physiol       Date:  2004-07-22       Impact factor: 5.182

6.  Cannabinoid-mediated diversity of antinociceptive efficacy of parecoxib in Wistar and Sprague Dawley rats in the chronic constriction injury model of neuropathic pain.

Authors:  Axel Becker; Gerd Geisslinger; Radovan Murín; Gisela Grecksch; Volker Höllt; Andreas Zimmer; Helmut Schröder
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-02-01       Impact factor: 3.000

7.  Molecular architecture of endocannabinoid signaling at nociceptive synapses mediating analgesia.

Authors:  Rita Nyilas; Laura C Gregg; Ken Mackie; Masahiko Watanabe; Andreas Zimmer; Andrea G Hohmann; István Katona
Journal:  Eur J Neurosci       Date:  2009-05-09       Impact factor: 3.386

8.  Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes.

Authors:  J Manzanares; Md Julian; A Carrascosa
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

9.  A decrease in anandamide signaling contributes to the maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain.

Authors:  Iryna A Khasabova; Sergey G Khasabov; Catherine Harding-Rose; Lia G Coicou; Bryan A Seybold; Amy E Lindberg; Christopher D Steevens; Donald A Simone; Virginia S Seybold
Journal:  J Neurosci       Date:  2008-10-29       Impact factor: 6.167

Review 10.  Dynamic regulation of the endocannabinoid system: implications for analgesia.

Authors:  Devi Rani Sagar; A Gemma Gaw; Bright N Okine; Stephen G Woodhams; Amy Wong; David A Kendall; Victoria Chapman
Journal:  Mol Pain       Date:  2009-10-08       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.